Charles Schwab’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.19M | Buy |
444,042
+372,042
| +517% | +$960K | ﹤0.01% | 2953 |
|
|
2026
Q1 | $160K | Buy |
+72,000
| New | +$129K | ﹤0.01% | 3324 |
|
|
2025
Q2 | – | Sell |
-135,487
| Closed | -$42.3K | – | 3549 |
|
|
2025
Q1 | $42.3K | Sell |
135,487
-26,321
| -16% | -$16.2K | ﹤0.01% | 3417 |
|
|
2024
Q4 | $151K | Hold |
161,808
| – | – | ﹤0.01% | 3356 |
|
|
2024
Q3 | $191K | Hold |
161,808
| – | – | ﹤0.01% | 3341 |
|
|
2024
Q2 | $124K | Hold |
161,808
| – | – | ﹤0.01% | 3464 |
|
|
2024
Q1 | $494K | Hold |
161,808
| – | – | ﹤0.01% | 3033 |
|
|
2023
Q4 | $521K | Sell |
161,808
-8,228
| -5% | -$28.1K | ﹤0.01% | 3064 |
|
|
2023
Q3 | $653K | Buy |
170,036
+7,389
| +5% | +$26.6K | ﹤0.01% | 2944 |
|
|
2023
Q2 | $533K | Buy |
162,647
+127,009
| +356% | +$431K | ﹤0.01% | 3020 |
|
|
2023
Q1 | $91.9K | Buy |
35,638
+16,186
| +83% | +$38.4K | ﹤0.01% | 3263 |
|
|
2022
Q4 | $36.2K | Hold |
19,452
| – | – | ﹤0.01% | 3424 |
|
|
2022
Q3 | $36K | Hold |
19,452
| – | – | ﹤0.01% | 3403 |
|
|
2022
Q2 | $42K | Hold |
19,452
| – | – | ﹤0.01% | 3417 |
|
|
2022
Q1 | $62K | Hold |
19,452
| – | – | ﹤0.01% | 3500 |
|
|
2021
Q4 | $63K | Hold |
19,452
| – | – | ﹤0.01% | 3488 |
|
|
2021
Q3 | $66K | Hold |
19,452
| – | – | ﹤0.01% | 3418 |
|
|
2021
Q2 | $77K | Sell |
19,452
-99,326
| -84% | -$392K | ﹤0.01% | 3313 |
|
|
2021
Q1 | $478K | Buy |
118,778
+10,896
| +10% | +$36.2K | ﹤0.01% | 3093 |
|
|
2020
Q4 | $250K | Buy |
107,882
+10,443
| +11% | +$48.7K | ﹤0.01% | 3226 |
|
|
2020
Q3 | $560K | Sell |
97,439
-3,412
| -3% | -$22.8K | ﹤0.01% | 2845 |
|
|
2020
Q2 | $744K | Buy |
100,851
+82,273
| +443% | +$385K | ﹤0.01% | 2714 |
|
|
2020
Q1 | $56K | Hold |
18,578
| – | – | ﹤0.01% | 3148 |
|
|
2019
Q4 | $78K | Buy |
+18,578
| New | +$58.7K | ﹤0.01% | 3110 |
|
|
2019
Q3 | – | Sell |
-73,229
| Closed | -$136K | – | 3189 |
|
|
2019
Q2 | $136K | Sell |
73,229
-27,369
| -27% | -$48.9K | ﹤0.01% | 3116 |
|
|
2019
Q1 | $179K | Buy |
100,598
+42,127
| +72% | +$105K | ﹤0.01% | 3043 |
|
|
2018
Q4 | $142K | Sell |
58,471
-1,216
| -2% | -$5.55K | ﹤0.01% | 3060 |
|
|
2018
Q3 | $339K | Buy |
59,687
+24,747
| +71% | +$188K | ﹤0.01% | 2971 |
|
|
2018
Q2 | $273K | Buy |
34,940
+645
| +2% | +$5.54K | ﹤0.01% | 3006 |
|
|
2018
Q1 | $243K | Buy |
34,295
+13,785
| +67% | +$112K | ﹤0.01% | 2942 |
|
|
2017
Q4 | $203K | Buy |
20,510
+6,010
| +41% | +$55.2K | ﹤0.01% | 2980 |
|
|
2017
Q3 | $125K | Hold |
14,500
| – | – | ﹤0.01% | 3052 |
|
|
2017
Q2 | $153K | Buy |
+14,500
| New | +$189K | ﹤0.01% | 3065 |
|
Other funds holding OVID
JT
EAM
RCM
AAA
ACM
Charles Schwab's OVID Position: Q2 2026 in Review
Charles Schwab increased its Ovid Therapeutics (OVID) stake by 517% in Q2 2026, buying an estimated $960K and bringing the position to 444,042 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2953.
Charles Schwab first reported a position in OVID in Q2 2017 and has held it in 33 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.
- Charles Schwab held 444,042 shares of Ovid Therapeutics worth $1.19M as of Q2 2026.
- Charles Schwab bought 372,042 Ovid Therapeutics shares in Q2 2026, an estimated $960K.
- Ovid Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2953 holding.
- Charles Schwab first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 33 quarters since.
- 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.